NEW YORK, August 14, 2026, 12:05 EDT – Capricor Therapeutics saw its stock price recover as the U.S. Food and Drug Administration reviews updated data from its Duchenne muscular dystrophy program, though the market remains cautious ahead of an expected announcement on August 22.
Shares of Capricor Therapeutics, Inc. NASDAQ:CAPR surged 51.7% to $6.38 in late-morning trade after the U.S. Food and Drug Administration agreed to assess additional 24-month data for deramiocel. The decision brings back a review that appeared near collapse two weeks earlier.
The rebound is significant, yet a full recovery has not occurred. Capricor shares traded at $6.38, still down 67.6% from their July 24 closing price, prior to the FDA’s criticism and an unfavorable advisory vote that wiped out the bulk of the company’s market value.
The gap provides investors with valuable information. The FDA agreeing to examine additional data alters the process and potentially the timeline, but it does not resolve the regulator’s concerns regarding trial methodology or cardiovascular advantage.
| CAPR price marker | Price | Change to Aug. 14 at 11:48 EDT |
|---|---|---|
| Aug. 14 intraday | $6.38 | Up 51.7% from previous close |
| Aug. 13 close | $4.21 | Up 51.7% |
| July 24 close | $19.70 | Down 67.6% |
| Dec. 31, 2025 close | $28.86 | Down 77.9% |
Capricor CEO Linda Marbán stated the company intends to update its application with 24-month upper-limb data from the Phase 3 HOPE-3 trial. The FDA could push back its existing August 22 decision deadline to evaluate the new information.
Marbán stated Thursday, “We continue to believe there is a path to approval for Deramiocel.” She pointed out that HOPE-3 focused on upper-limb function, whereas the advisory panel’s vote concerned cardiomyopathy. Capricor’s August 13 filing
The difference is significant. The panel voted three for and nine against the adequacy of current evidence demonstrating effectiveness for DMD cardiomyopathy. FDA staff raised concerns over major changes to analyses conducted after the study and also highlighted questions about patients’ normal heart function at baseline.
| Regulatory evidence | Verified result | Investor reading |
|---|---|---|
| Advisory vote | 3 yes, 9 no | Cardiomyopathy effectiveness seen as negative |
| HOPE-3 upper-limb endpoint | p=0.029 | Primary outcome statistically significant |
| Overall LVEF result | p=0.09; 1.8-point difference | Below usual significance threshold |
| Pre-specified cardiomyopathy subgroup | p=0.02 | Subgroup result provides additional support |
| New filing | 24-month upper-limb data | Potential changes to review and timing |
Capricor has some breathing room based on its balance sheet, but no guarantees. As of June 30, its cash and marketable securities totaled $237.9 million. With 58.1 million shares outstanding and the late-morning share price, this amount represented about 64% of the company’s preliminary equity valuation.
Operating expenses climbed 55% in the second quarter from a year earlier as the company ramped up manufacturing and launch activities. Capricor posted no revenue for the first half.
| Financial measure | Latest | Comparison | Change |
|---|---|---|---|
| Cash and marketable securities | $237.9 million, June 30 | $318.1 million, Dec. 31 | -25.2% |
| Q2 operating expenses | $42.9 million | $27.7 million a year earlier | +55.0% |
| Q2 net loss | $40.7 million | $25.9 million a year earlier | +57.3% |
| First-half revenue | $0 | $0 a year earlier | No change |
Analyst price targets now indicate highly divergent expectations. Some optimistic projections still top $50, while downgraded targets after the briefing group between $7 and $10. This disparity offers more insight than the mean value.
| Firm | Latest recommendation | Target | Action date |
|---|---|---|---|
| Alliance Global Partners | Hold | Not stated | July 28 |
| Roth/MKM | Hold | $7 | July 27 |
| B. Riley | Hold | $10 | July 27 |
| Jones Trading | Buy | $51 | July 27 |
| H.C. Wainwright | Buy | $60 | July 27 |
Capricor has reduced the pace of its commercial expansion, awaiting further regulatory guidance. The manufacturing facility in San Diego continues to prepare for the planned initial launch, but non-deramiocel projects are paused. The firm anticipates arbitration later this fall regarding its U.S. distribution deal with NS Pharma.
Risks: The FDA could still turn down deramiocel, ask for additional studies, or limit the approved label. Any extension of the deadline would extend uncertainty and keep cash burn elevated. Approval alone would not address risks related to manufacturing, market adoption, reimbursement, or ongoing partner disputes.
At present, the shares warrant reconsideration rather than signaling a full regulatory reset. The upcoming key development is how the FDA addresses the amendment and the August 22 timeline.
Related articles: Biotechnology
